Cargando…

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)

BACKGROUND: Patients with glioblastoma (GBM) have a poor prognosis and limited effective treatment options. Bevacizumab has been approved for treatment of recurrent GBM, but there is questionable survival benefit. Based on preclinical and early clinical data indicating that CD105 upregulation may re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galanis, Evanthia, Anderson, S Keith, Twohy, Erin, Butowski, Nicholas A, Hormigo, Adilia, Schiff, David, Omuro, Antonio, Jaeckle, Kurt A, Kumar, Shaji, Kaufmann, Timothy J, Geyer, Susan, Kumthekar, Priya U, Campian, Jian, Giannini, Caterina, Buckner, Jan C, Wen, Patrick Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154335/ https://www.ncbi.nlm.nih.gov/pubmed/35664553 http://dx.doi.org/10.1093/noajnl/vdac041

Ejemplares similares

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
por: Liu, Yingmiao, et al.
Publicado: (2014)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
por: Kumthekar, Priya, et al.
Publicado: (2022)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
por: Mehta, C R, et al.
Publicado: (2019)

Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
por: Ellingson, Benjamin M, et al.
Publicado: (2021)

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
por: Brossa, Alessia, et al.
Publicado: (2018)

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
por: Cohen, Adam L., et al.
Publicado: (2020)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion
por: Huveldt, Deborah, et al.
Publicado: (2013)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
por: Kou, Furong, et al.
Publicado: (2021)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
por: Thomas, Alissa, et al.
Publicado: (2018)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
por: Plotkin, Scott R, et al.
Publicado: (2023)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
por: Leone, Jose Pablo, et al.
Publicado: (2020)

Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
por: Ascha, Mustafa S., et al.
Publicado: (2019)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
por: Demarchi, Martin, et al.
Publicado: (2021)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2014)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
por: Bota, Daniela A, et al.
Publicado: (2018)

An Orthopedic Clinic of 1174 A.D.
por: Cravener, Edward K.
Publicado: (1931)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
por: Javle, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_km8hbu25rv1pgtq9ibtatdgl5s